Additional Information

Description

Wegovy (Semaglutide) 2.4 mg is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for chronic weight management in adults with obesity or those who are overweight with at least one weight-related comorbid condition. It is also utilized in the management of type 2 diabetes mellitus. Semaglutide promotes weight loss and glycemic control by enhancing insulin secretion, reducing glucagon levels, and delaying gastric emptying.

The medication is administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm. Injection sites should be rotated to reduce the risk of lipodystrophy or irritation. Dose escalation is often required to minimize gastrointestinal side effects. When used with insulin or other hypoglycemic agents, the risk of hypoglycemia increases, necessitating careful monitoring and potential dosage adjustments.

Wegovy carries a boxed warning regarding the potential risk of thyroid C-cell tumors. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Patients should be monitored for signs of pancreatitis, and gastrointestinal symptoms such as nausea, vomiting, and diarrhea, which are among the most common adverse effects.